Abstract
The objective of the present study was an evaluation of the incidence and risk factors
for erroneous histopathological diagnosis of low-grade glioma after stereotactic biopsy.
Twenty-eight tumors diagnosed as low-grade glioma after stereotactic biopsy and surgically
resected thereafter were analyzed. There were 13 astrocytomas, 7 oligodendrogliomas,
and 8 mixed gliomas. All neoplasms had a lobar location. Seven tumors had contrast
enhancement on MRI. The number of tissue samples obtained during stereotactic biopsy
was one in 19 cases, two in 4, and three or more in 5. Complete diagnostic agreement
in tumor typing and grading after stereotactic biopsy and surgical resection was attained
in 10 cases (36%). Agreement in tumor typing was marked in 16 cases (57%). Erroneous
typing was more frequent in tumors with an MIB-1 index of less than 3% (P=0.0629)
and mixed gliomas (P=0.0801). Overgrading of WHO grade I tumors was marked in 3 cases
(11%) and undergrading of WHO grade III gliomas in 8 cases (28%). Tumor undergrading
was more frequent in cases with an MIB-1 index of more than 3% (P=0.0045). The MIB-1
index detected after stereotactic biopsy was nearly always lower compared with those
established after surgical resection (P<0.0001). In conclusion, the histopathological
diagnosis of low-grade glioma established after stereotactic biopsy is associated
with a substantial risk of inaccuracy. Tumors with low proliferative activity and
mixed gliomas are especially susceptible for erroneous tumor typing. Undergrading
of high-grade gliomas may be suspected if the MIB-1 index in the tumor specimen constitutes
more, than 3%.
Key words
stereotactic biopsy - diagnostic accuracy - low-grade glioma - MIB-1 index
References
- 1
Chandrasoma PT, Smith MM, Apuzzo MLJ.
Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy
and resected surgical specimen.
Neurosurgery.
1989;
24
160-165
- 2
Revesz T, Scaravilli F, Coutinho L. et al .
Reliability of histological diagnosis including grading in gliomas biopsied by image-guided
stereotactic technique.
Brain.
1993;
116
781-793
- 3
Kim JE, Kim DG, Paek SH. et al .
Stereotactic biopsy for intracranial lesions: reliability and its impact on the planning
of treatment.
Acta Neurochir (Wien).
2003;
145
547-555
- 4
Glantz MJ, Burger PC, Herndon JE II. et al .
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic
gliomas.
Neurology.
1991;
41
1741-1744
- 5
Grunert P, Ungersbock K, Bohl J. et al .
Results of 200 intracranial stereotactic biopsies.
Neurosurg Rev.
1994;
17
59-66
- 6
Vaquero J, Martinez R, Manrique M.
Stereotactic biopsy for brain tumors: is it always necessary?.
Surg Neurol.
2000;
53
432-438
- 7
Jackson RJ, Fuller GN, Abi-Said D. et al .
Limitations of stereotactic biopsy in the initial management of gliomas.
Neurooncology.
2001;
3
193-200
- 8
MacGirt MJ, Villavicencio AT, Bulsara KR. et al .
MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and
surgical resection specimen.
Surg Neurol.
2003;
59
277-282
- 9 Kleihues P, Cavenee WK. eds.
Pathology and genetics of tumours of the Nervous System. Lyon: IARC Press 2000
- 10
Mork SJ, Halvorsen TB, Lindegaard K-F. et al .
Oligodendroglioma: histologic evaluation and prognosis.
J Neuropathol Exp Neurol.
1986;
45
65-78
- 11
Aker FV, Hakan T, Karadereler S. et al .
Accuracy and diagnostic yield of stereotactic biopsy in the diagnosis of brain masses:
comparison of results of biopsy and resected surgical specimens.
Neuropathology.
2005;
25
207-213
- 12
Okamoto Y, Patre PL Di, Burkhard C. et al .
Population-based study on incidence, survival rates, and genetic alterations of low-grade
diffuse astrocytomas and oligodendrogliomas.
Acta Neuropathol (Berl).
2004;
108
49-56
- 13
Ohgaki H, Kleihues P.
Population-based studies on incidence, survival rates, and genetic alterations in
astrocytic and oligodendroglial gliomas.
J Neuropathol Exp Neurol.
2005;
64
479-489
- 14
Krouwer HCJ, Duinen SG van, Kamphorst W. et al .
Oligoastrocytomas: a clinicopathological study of 52 cases.
J Neurooncol.
1997;
33
223-238
- 15
Grier JT, Batchelor T.
Low-grade gliomas in adults.
Oncologist.
2006;
11
681-693
- 16
Lebrun C, Fontaine D, Bourg V. et al .
Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV
chemotherapy.
Eur J Neurol.
2007;
14
391-398
- 17
Dean BL, Drayer BP, Bird CR. et al .
Gliomas: classification with MR imaging.
Radiology.
1990;
174
411-415
- 18
Law M, Yang S, Wang H. et al .
Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging
and proton MR spectroscopic imaging compared with conventional MR imaging.
AJNR Am J Neuroradiol.
2003;
24
1989-1998
- 19
Kondziolka D, Lunsford LD, Martinez AJ.
Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult
supratentorial (low-grade) astrocytoma.
J Neurosurg.
1993;
79
533-536
- 20
Barker FG II, Chang SM, Huhn SL. et al .
Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral
tumors.
Cancer.
1997;
80
936-941
- 21
Ginsberg LE, Fuller GN, Hashmi M. et al .
The significance of lack of MR contrast enhancement of supratentorial brain tumors
in adults: histopathological evaluation of a series.
Surg Neurol.
1998;
49
436-440
- 22
Scott JN, Brasher PMA, Sevick RJ. et al .
How often are nonenhancing supratentorial gliomas malignant? A population study.
Neurology.
2002;
59
947-949
- 23
Buckner JC, Gesme Jr D, O`Fallon JR. et al .
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations
with chromosomal abnormalities.
J Clin Oncol.
2003;
21
251-255
- 24
Massager N, David P, Goldman S. et al .
Combined magnetic resonance imaging- and positron emission tomography-guided stereotactic
biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients.
J Neurosurg.
2000;
93
951-957
- 25
Maia Jr ACM, Malheiros SMF, da Rocha AJ. et al .
Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role
of perfusion-weighted magnetic resonance imaging.
J Neurosurg.
2004;
101
970-976
- 26
Floeth FW, Pauleit D, Wittsack H-J. et al .
Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with
[18F] fluoro-ethyl-L-tyrosine and magnetic resonance spectroscopy.
J Neurosurg.
2005;
102
318-327
- 27
Kelly PJ, Daumas-Duport C, Kispert DB. et al .
Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms.
J Neurosurg.
1987;
66
865-874
- 28
Plunkett R, Allison RR, Grand W.
Stereotactic neurosurgical biopsy is an underutilized modality.
Neurosurg Rev.
1999;
22
117-120
- 29
Yu X, Liu Z, Tian Z. et al .
Stereotactic biopsy for intracranial space-occupying lesions: clinical analysis of
550 cases.
Stereotact Funct Neurosurg.
2000;
75
103-108
- 30
Kim L, Hochberg FH, Thornton AF. et al .
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for Grade III and Grade
IV oligoastrocytomas.
J Neurosurg.
1996;
85
602-607
- 31
Blaauw G, Braakman R.
Pitfalls in diagnostic stereotactic brain surgery.
Acta Neurochir Suppl.
1988;
42
161-165
- 32
Feiden W, Steude U, Bise K. et al .
Accuracy of stereotactic brain tumor biopsy: comparison of the histologic findings
in biopsy cylinders and resected tumor tissue.
Neurosurg Rev.
1991;
14
51-56
- 33
Soo TM, Bernstein M, Provias J. et al .
Failed stereotactic biopsy in a series of 518 cases.
Stereotact Funct Neurosurg.
1996;
64
183-196
- 34
Coons SW, Johnson PC.
Regional heterogeneity in the proliferative activity of human gliomas as measured
by the Ki-67 labeling index.
J Neuropathol Exp Neurol.
1993;
52
609-618
- 35
Mittler MA, Walters BC, Stopa EG.
Observer reliability in histological grading of astrocytoma stereotactic biopsies.
J Neurosurg.
1996;
85
1091-1094
- 36
Daumas-Duport C, Scheithauer B, O`Fallon J. et al .
Grading of astrocytomas: a simple and reproducible method.
Cancer.
1988;
62
2152-2165
- 37
Hemm S, Vayssiere N, Zanca M. et al .
Thallium SPECT-based stereotactic targeting for brain tumor biopsies.
Stereotact Funct Neurosurg.
2004;
82
70-76
- 38
Son BC, Kim MC, Choi BG. et al .
Proton magnetic resonance chemical shift imaging (1 H CSI)-directed stereotactic biopsy.
Acta Neurochir (Wien).
2001;
143
45-50
- 39
Hall WA, Truwit CL.
1.5 T spectroscopy-supported brain biopsy.
Neurosurg Clin N Am.
2005;
16
165-172
Correspondence
Y. MuragakiMD, PhD
Faculty of Advanced Techno-Surgery
Institute of Advanced Biomedical Engineering and Science
Graduate School of Medicine
Tokyo Women’s Medical University
8-1 Kawada-cho
Shinjuku-ku
Tokyo 162-8666
Japan
Phone: +81/3/3353 81 11 ext.399 89
Fax: +81/3/5361 77 96
Email: ymuragaki@abmes.twmu.ac.jp